KLOW

What is KLOW?

KLOW is the informal name for a four-peptide blend: KPV (lysine-proline-valine, the C-terminal tripeptide of α-MSH), GHK-Cu (copper complex of glycyl-L-histidyl-L-lysine), BPC-157 (synthetic 15-aa peptide), and TB-500 (generally N-acetylated thymosin beta-4 17–23, `Ac-LKKTETQ`).

The name is a variation of GLOW (GHK-Cu + BPC-157 + TB-500). KLOW adds KPV. It is not a single new molecule—four chemically distinct peptides lyophilized into one vial, each with its own identity, mechanism, evidence base, and analytical requirements.

Standard KLOW composition

The 50/10/10/10 label must list which component receives the 50 mg allocation. In the standard formulation, GHK-Cu is the 50 mg component. Some online pages reverse the order in prose and incorrectly assign 50 mg to BPC-157.

Identity checks before interpreting a KLOW label

TB-500 versus thymosin beta-4: Full-length Tβ4 has 43 amino acids. Products sold as TB-500 have been identified as `Ac-LKKTETQ`. Full-length Tβ4 clinical research is not a TB-500 fragment dosing study.

GHK versus GHK-Cu: Confirm the intended copper complex, copper content, peptide identity, and the basis of the stated milligram quantity.

Free base versus acetate: Labels should identify salt form and whether stated mass includes counterions and water—important for analytical potency and cross-supplier comparison.

Current research and compounding status

KLOW itself has not undergone a regulatory review as a fixed combination. In July 2026, an FDA advisory committee narrowly recommended that BPC-157, KPV, and TB-500-related bulk substances be eligible for the 503A compounding list. The votes were advisory and did not evaluate the KLOW blend, its 50/10/10/10 ratio, or its dosing schedule. GHK-Cu was not part of that vote; FDA treats non-injectable and injectable GHK-Cu nominations differently.

No US prescribing information establishes a KLOW dose.

Has the exact KLOW combination been studied?

No controlled human or animal dose-ranging study of the exact 50/10/10/10 KLOW blend was identified. The four components cannot be assumed to remain equally stable in one vial, share a common ideal frequency, or produce additive benefits. Fixed-ratio convenience is not pharmacological optimization.

Human research on the individual components

Human studies of full-length thymosin beta-4 tested a molecule many times larger than `Ac-LKKTETQ`. Route, clearance, tissue distribution, immunogenicity, and biological activity can therefore differ substantially.

KLOW research dosage

Modern protocol pages most consistently report 2–4 mg of total KLOW blend per administration. Because GHK-Cu is 62.5% of the vial and each other component is 12.5%, the total blend number must always be translated into four component amounts.

Complete reported KLOW research protocol

The following 12-week front-loaded protocol is the most internally coherent recurring schedule: phases are explicit, per-component exposures are transparent, and approximately two 80 mg vials cover the cycle (128 mg total blend ≈ 1.6 vials before handling loss).

This chart assumes an 80 mg vial reconstituted to 2 mL (40 mg/mL). On a U-100 syringe, 10 units = 0.10 mL and 5 units = 0.05 mL. The front-loaded protocol does not escalate—it begins higher and steps down. That structure is a “loading then maintenance” story, not KLOW pharmacokinetics.

Early-stop criteria (examples): severe/progressive injection-site reaction; allergic symptoms (rash, facial swelling, breathing difficulty); persistent dizziness, headache, nausea, or fatigue; marked BP/HR change; new neurological symptoms; infection signs; unexpected worsening of the target condition. Urgent symptoms require medical evaluation—not a dose adjustment.

Alternative daily step-up research protocol

Some protocol pages use gradual daily titration (often assuming 3 mL diluent ≈ 26.67 mg/mL). Weeks 1–8 use 252 mg total blend (≈3.15 vials); adding weeks 9–12 raises the total to 364 mg (≈4.55 vials).

No comparative study shows that this additional exposure improves outcomes. The 6 mg daily phase should be labeled a higher-exposure community protocol, not a standard clinical target.

KLOW reconstitution and concentration math

Diluent volume changes the draw volume, not the amount of each peptide in a given total-mass dose. The syringe unit number is not a dose by itself: “10 units of KLOW” delivers 4 mg after a 2 mL dilution but only ≈2.67 mg after a 3 mL dilution.

Reported KLOW dosage range

Anecdotal versus clinically studied dosing

Why the four peptides are combined

The combination covers several stages of a generalized repair narrative: inflammation control, cell migration, vascular signaling, and matrix remodeling. Biological pathways are not isolated job assignments—all four may affect overlapping inflammatory and angiogenic processes, and coadministration could produce interactions not predicted from monotherapy studies.

Component evidence in more detail

1. KPV — reduced inflammatory activity in mouse colitis; PepT1 transport in epithelial models. Oral/colon-targeted findings do not establish systemic SC dosing.
2. GHK-Cu — extensive in-vitro and topical research; mixed topical clinical results (diabetic ulcers vs CO₂-laser resurfacing). More relevant to skin than injectable KLOW claims.
3. BPC-157 — numerous rodent models; human evidence mainly small uncontrolled reports plus a two-person IV safety pilot. Soft-tissue findings remain largely unvalidated in humans.
4. TB-500 — `LKKTETQ` region participates in actin binding in preclinical models. Full-length Tβ4 IV/topical human studies do not establish a dose for the shorter acetylated fragment.

Dosage evidence ladder

Safety and adverse effects

No exact-combination adverse-event rate exists. Fixed-ratio convenience means you cannot reduce GHK-Cu without simultaneously reducing KPV, BPC-157, and TB-500—the central experimental-control tradeoff of KLOW.

Storage and stability

Community protocols usually specify refrigerated storage at 2–8°C after reconstitution, protection from light, gentle swirling rather than shaking, and use within approximately 28 days. No published stability study was identified for the complete four-component mixture under these conditions.

A clear blue solution does not prove that all four peptides remain intact. The front-loaded loading phase consumes one vial within four weeks (aligning with the common 28-day convention); the maintenance phase spans longer than one vial-use window, so a second vial’s opening date must be tracked independently.

Anti-doping status

BPC-157 and thymosin beta-4 derivatives are prohibited under the WADA framework. Because KLOW contains both BPC-157 and TB-500, it is incompatible with tested sport regardless of “recovery blend” marketing.

Bottom line

KLOW is a fixed 5:1:1:1 blend. The standard 80 mg vial contains 50 mg GHK-Cu and 10 mg of each remaining peptide. The most commonly reported per-administration range is 2–4 mg total blend (≈1.25–2.5 mg GHK-Cu plus 250–500 mcg each of KPV, BPC-157, and TB-500).

The most coherent complete community protocol uses 4 mg five times weekly for four weeks, then 2 mg three times weekly for eight weeks, then a 4–8-week washout. A daily 2 → 4 → 6 mg titration also circulates with substantially greater exposure and no stronger evidence.

Confirm true 50/10/10/10 composition, TB-500 as Ac-LKKTETQ, component-specific potency, copper-complex identity, and stability of all four peptides after mixing — before trusting any unit chart.

Frequently asked questions

References

• FDA

  July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting

  Advisory votes — not a KLOW blend evaluation.

• FDA

  Bulk drug substances nominated for use in compounding

  Updated May 2026; GHK-Cu category distinctions.

• Pickart L, Margolina A.

  Regenerative and protective actions of GHK-Cu

  2018 review — topical/lab context.

• Mulder GD et al.

  Topical GHK-Cu in diabetic neuropathic ulcers

  1994 — not injectable KLOW dosing.

• Dalmasso G et al.

  PepT1-mediated KPV uptake and intestinal inflammation

  2008.

• Brzoska T et al.

  KPV in murine colitis models

  2008.

• Esposito S et al.

  Identification of acetylated thymosin beta-4 17–23 in TB-500

  2012.

• Ho ENM et al.

  TB-500 chemistry and detection

  2012.

• Morris DC et al.

  Thymosin beta-4 active sites and biological activity

  2010.

• BPC-157 IV pilot

  Safety of IV BPC-157 in two adults

  2025 — not SC blend validation.

• Sports medicine review

  Injectable peptide therapy in orthopaedic and sports medicine

  2025.

• WADA

  2026 Prohibited List

  BPC-157 and Tβ4 derivatives prohibited.